Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

3.2%

1 terminated out of 31 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results83% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (4)
P 1 (8)
P 2 (9)
P 3 (3)

Trial Status

Recruiting11
Active Not Recruiting8
Completed5
Unknown3
Enrolling By Invitation1
Not Yet Recruiting1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT06157151Phase 2Recruiting

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

NCT05307939Phase 2Recruiting

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT06508138Phase 1Enrolling By Invitation

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

NCT04857528Recruiting

Detecting HPV DNA in Anal and Cervical Cancers

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT07425054Phase 2Not Yet Recruiting

HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer

NCT06305676Recruiting

Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)

NCT03260023Phase 1Active Not RecruitingPrimary

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

NCT03978689Phase 1Completed

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

NCT05262010Phase 3Recruiting

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

NCT06640283Phase 2RecruitingPrimary

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

NCT06756269Phase 2Recruiting

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

NCT05973487Phase 1Active Not Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05976828Phase 1Active Not RecruitingPrimary

IBRX-042 In Participants With HPV-Associated Tumors

NCT05247853Completed

HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV

NCT05814549Active Not Recruiting

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

NCT03795610Phase 2Completed

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

NCT06574087Not ApplicableRecruitingPrimary

Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.

NCT06234748Phase 2Active Not Recruiting

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

Scroll to load more

Research Network

Activity Timeline